Stein Steven H — SEC Form 4 filings
SEC reporting owner CIK 1673776. 23 Form 4 filings on record with FilingPulse; latest filed 2026-07-20.
Transaction summary — filings shown
Covers all 23 filings on record, filed 2024-01-22 to 2026-07-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 9 filings — 116,263 shares, $10,733,979 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 35.
- Largest priced transaction: sale of 28,237 shares @ $113.05 ($3,192,193) in INCYTE CORP, filed 2026-07-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| INCYTE CORP (INCY) | CMO & Head of Late-Stage Dev. | 21 | — | 10 legs · 116,263 sh · $10,733,979 | 33 |
| Repare Therapeutics Inc. (RPTX) | Director | 1 | — | — | 1 |
| Theseus Pharmaceuticals, Inc. (THRX) | Director | 1 | — | — | 1 |
Form 4 filings — Stein Steven H
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-20 | 4 | INCYTE CORP (INCY) | Sale (S): 1,877 @ $114.73 · Grant/award (A): 9,798 @ $0 · Grant/award (A): 24,496 (derivative) @ $0 · Grant/award (A): 42,298 (derivative) @ $0 | EDGAR |
| 2026-07-16 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 21,830 @ $114.88 · Sale (S): 28,237 @ $113.05 · Tax withholding (F): 3,088 @ $115.09 | EDGAR |
| 2026-07-07 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 2,177 @ $116.86 | EDGAR |
| 2026-05-20 | 4/A | INCYTE CORP (INCY) | Grant/award (A): 44,124 @ $0 | EDGAR |
| 2026-04-17 | 4 | INCYTE CORP (INCY) | Grant/award (A): 39,049 @ $0 | EDGAR |
| 2026-01-21 | 4 | INCYTE CORP (INCY) | Grant/award (A): 19,932 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | INCYTE CORP (INCY) | Sale (S): 15,634 @ $101.70 | EDGAR |
| 2026-01-05 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 13,292 @ $98.77 | EDGAR |
| 2025-12-03 | 4 | INCYTE CORP (INCY) | Sale (S): 2,559 @ $102.96 · Tax withholding (F): 17,093 @ $102.04 · Sale (S): 20,105 @ $102.51 | EDGAR |
| 2025-11-07 | 4 | INCYTE CORP (INCY) | Option exercise (M): 1,194 @ $83.83 · Option exercise (M): 2,995 @ $95.76 · Option exercise (M): 1,044 @ $95.76 · Sale (S): 5,233 @ $102.20 · Option exercise (M): 1,194 (derivative) @ $0 · Option exercise (M): 2,995 (derivative) @ $0 · +1 more | EDGAR |
| 2025-07-23 | 4 | INCYTE CORP (INCY) | Sale (S): 3,706 @ $67.94 | EDGAR |
| 2025-07-16 | 4 | INCYTE CORP (INCY) | Sale (S): 14,952 @ $68.47 · Tax withholding (F): 1,555 @ $69.98 · Tax withholding (F): 1,596 @ $68.25 · Grant/award (A): 12,277 @ $0 · Grant/award (A): 30,692 (derivative) @ $0 · Grant/award (A): 27,629 (derivative) @ $0 | EDGAR |
| 2025-07-07 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 12,714 @ $68.17 | EDGAR |
| 2025-04-03 | 4 | INCYTE CORP (INCY) | Grant/award (A): 37,198 @ $0 · Grant/award (A): 20,967 @ $0 | EDGAR |
| 2025-01-22 | 4 | INCYTE CORP (INCY) | Sale (S): 12,352 @ $72.69 · Grant/award (A): 28,202 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 10,692 @ $72.46 | EDGAR |
| 2024-08-14 | 4 | INCYTE CORP (INCY) | Sale (S): 11,608 @ $60.63 | EDGAR |
| 2024-07-17 | 4 | INCYTE CORP (INCY) | Grant/award (A): 13,895 @ $0 · Tax withholding (F): 1,555 @ $64.25 · Grant/award (A): 31,088 (derivative) @ $0 | EDGAR |
| 2024-07-03 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 8,316 @ $59.02 | EDGAR |
| 2024-06-20 | 4 | Repare Therapeutics Inc. (RPTX) | Grant/award (A): 54,000 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | INCYTE CORP (INCY) | Grant/award (A): 7,377 @ $0 | EDGAR |
| 2024-02-14 | 4 | Theseus Pharmaceuticals, Inc. (THRX) | Disposition to issuer (D): 3,250 (derivative) | EDGAR |
| 2024-01-22 | 4 | INCYTE CORP (INCY) | Grant/award (A): 30,580 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1673776 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →